Literatura

1. ↑Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
2. ↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
3. ↑Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
4. ↑World Health Organization (2007). „International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98”. WHO Drug Information 21 (4): 341. 
5. ↑Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). „Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders”. Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370–5. DOI:10.1073/pnas.092012099. PMC 122955. PMID 11959912. 
6. ↑Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). „An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders”. CNS drug reviews 11 (1): 53–68. DOI:10.1111/j.1527-3458.2005.tb00035.x. PMID 15867952. 
7. ↑„Second-quarter 2008 results”. Press Release. Sanofi-Aventis. 31. 07. 2008.. Arhivirano izoriginala na datum 2008-12-06. Pristupljeno 10. 06. 2009. »It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).« 

Vanjske veze